Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is a strong investment opportunity due to its diverse portfolio of key products in highly profitable sectors such as cancer, cardiometabolic diseases, and immunology. This, combined with the company's projected revenue and EPS growth, as well as its strong financial position, make it a promising stock for long-term investors. Additionally, potential risks such as slowing growth, negative clinical data, and industry headwinds can be mitigated by the company's solid research and development efforts and strategic acquisitions.

Bears say

Eli Lilly is reporting excellent sales and a positive outlook for their range of drugs, but a closer look into their products reveals concerns about safety and the effectiveness of their newly launched drug, Foundayo. While their earnings and revenue projections continue to be strong, the negative impact of any potential safety issues can't be ignored - leading to a negative outlook on the stock. Additionally, while the company is making progress with their new drug launch, it still lags behind its competitor, Oral Wegovy, making it difficult to see significant growth in the near term.

Eli Lilly (LLY) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 19 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,223.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,223.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.